NPHLA Daily
NPHLA Daily
Friday, October 23, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 4 trial updates
NPHLA tracked 4 new official records on this desk today: 4 trial updates. First: New trial registered: A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
Metabolic signal
New trial registered: ENI-SPIRE-2 (A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and…)
Phase 3, Hoffmann-La Roche. Conditions: Type 2 Diabetes Mellitus. Interventions: Enicepatide; Tirzepatide. Investigational: trial-stage therapies are not approved for the use studied.
Regulatory signal
What changed today in Regulatory: 1 safety alert
NPHLA tracked 1 new official record on this desk today: 1 safety alert. First: Update: Import Alert for Certain Olympus Medical Devices Manufactured in Japan - Letter to Health Care Providers
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 4 trial updates
- What changed today in Regulatory: 1 safety alert
- New trial registered: ENI-SPIRE-2 (A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and…) (ClinicalTrials.gov (U.S. National Library of Medicine))
- New trial registered: Switch TZP (Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide) (ClinicalTrials.gov (U.S. National Library of Medicine))
- New trial registered: A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes (ClinicalTrials.gov (U.S. National Library of Medicine))
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.